JP2003535076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003535076A5 JP2003535076A5 JP2002500835A JP2002500835A JP2003535076A5 JP 2003535076 A5 JP2003535076 A5 JP 2003535076A5 JP 2002500835 A JP2002500835 A JP 2002500835A JP 2002500835 A JP2002500835 A JP 2002500835A JP 2003535076 A5 JP2003535076 A5 JP 2003535076A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- diseases
- cells
- compound according
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 230000002280 anti-androgenic effect Effects 0.000 description 5
- 239000000051 antiandrogen Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- -1 halide ion Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 3
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101100218425 Gallus gallus BCL2L1 gene Proteins 0.000 description 3
- 108700041567 MDR Genes Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- JJHSUAVSFZLXNL-UHFFFAOYSA-N I.CCCCCCCC(=O)OC(=S)CCC Chemical compound I.CCCCCCCC(=O)OC(=S)CCC JJHSUAVSFZLXNL-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical group OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000002741 leukoplakia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- XEVZURDMZKIWMB-UHFFFAOYSA-N s-methyl 4-methyl-4-morpholin-4-ylpent-2-ynethioate Chemical compound CSC(=O)C#CC(C)(C)N1CCOCC1 XEVZURDMZKIWMB-UHFFFAOYSA-N 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical group SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- BNRQMHZZZUFXNK-UHFFFAOYSA-N 4-(2-methylbut-3-yn-2-yl)morpholine Chemical compound C#CC(C)(C)N1CCOCC1 BNRQMHZZZUFXNK-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical group O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010049422 Precancerous skin lesion Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- BSGLGIKDBHPSMZ-UHFFFAOYSA-N n,n,2-trimethylbut-3-yn-2-amine Chemical compound CN(C)C(C)(C)C#C BSGLGIKDBHPSMZ-UHFFFAOYSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- XFLSMXBNQSTUIY-UHFFFAOYSA-N s-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate Chemical compound CSC(=O)C#CC(C)(C)N(C)C XFLSMXBNQSTUIY-UHFFFAOYSA-N 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR00/07029 | 2000-05-31 | ||
| FR0007029A FR2809727B1 (fr) | 2000-05-31 | 2000-05-31 | Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
| PCT/FR2001/001694 WO2001092220A1 (fr) | 2000-05-31 | 2001-05-31 | Composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003535076A JP2003535076A (ja) | 2003-11-25 |
| JP2003535076A5 true JP2003535076A5 (enExample) | 2011-10-27 |
| JP4855626B2 JP4855626B2 (ja) | 2012-01-18 |
Family
ID=8850863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002500835A Expired - Lifetime JP4855626B2 (ja) | 2000-05-31 | 2001-05-31 | 製薬分野における新規なアミノチオールエステル誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8026231B2 (enExample) |
| EP (1) | EP1296946B1 (enExample) |
| JP (1) | JP4855626B2 (enExample) |
| AR (1) | AR028122A1 (enExample) |
| AT (1) | ATE264839T1 (enExample) |
| AU (1) | AU2001274171A1 (enExample) |
| DE (1) | DE60102925T2 (enExample) |
| ES (1) | ES2219530T3 (enExample) |
| FR (1) | FR2809727B1 (enExample) |
| WO (1) | WO2001092220A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2983492B1 (fr) * | 2011-12-06 | 2015-10-30 | Advanced Biodesign | Procede ex vivo de purge tumorale d'un echantillon biologique |
| PL3362094T3 (pl) * | 2015-10-15 | 2021-10-11 | Advanced Biodesign | Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika |
| LT3362056T (lt) | 2015-10-15 | 2021-05-10 | Advanced Biodesign | Aminotiolesterio junginiai arba jų farmaciniu požiūriu priimtinos druskos, skirti naudoti vėžio gydyme |
| FR3047734B1 (fr) * | 2016-02-17 | 2019-09-06 | Advanced Biodesign | Procede de preparation de composes aminothiolester et leurs sels |
| US20220265845A1 (en) * | 2019-07-31 | 2022-08-25 | Advanced Biodesign | Aminothiolester compounds and uses thereof |
| EP4035666A1 (en) | 2021-01-29 | 2022-08-03 | Advanced Biodesign | Aminothiolester compound or derivative thereof for use as an immunomodulatory agent |
| FR3119314B1 (fr) | 2021-01-29 | 2025-01-10 | Advanced Biodesign | Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable |
| WO2025229179A1 (en) | 2024-05-03 | 2025-11-06 | Advanced Biodesign | Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051528A (en) * | 1990-04-24 | 1991-09-24 | Eastman Kodak Company | Recovery process for ethylene glycol and dimethylterephthalate |
| JPH0797350A (ja) * | 1993-08-02 | 1995-04-11 | Mitsubishi Chem Corp | ベンゾイルアセチレン誘導体 |
| FR2761606B1 (fr) * | 1997-04-08 | 1999-05-14 | Cird Galderma | Utilisation de derives aminothiolesters dans le domaine pharmaceutique |
| KR100488985B1 (ko) | 1997-12-02 | 2005-05-11 | 하인리히 스무다 | 폴리에틸렌테레프탈레이트 폐기물로부터 테레프탈산 및 에틸렌글리콜을 회수하는 방법 |
| FR2777001B1 (fr) * | 1998-04-01 | 2000-06-09 | Cird Galderma | Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses |
| EP1227075B1 (en) | 1999-10-22 | 2009-07-29 | Teijin Limited | Method for separating and recovering dimethyl terephthalate and ethylene glycol from polyester waste |
| JP3808672B2 (ja) * | 1999-11-26 | 2006-08-16 | 東洋製罐株式会社 | 回収ポリエチレンテレフタレート粉砕品からのテレフタル酸の工業的回収方法 |
-
2000
- 2000-05-31 FR FR0007029A patent/FR2809727B1/fr not_active Expired - Fee Related
-
2001
- 2001-05-30 AR ARP010102577A patent/AR028122A1/es unknown
- 2001-05-31 JP JP2002500835A patent/JP4855626B2/ja not_active Expired - Lifetime
- 2001-05-31 EP EP01940654A patent/EP1296946B1/fr not_active Expired - Lifetime
- 2001-05-31 AU AU2001274171A patent/AU2001274171A1/en not_active Abandoned
- 2001-05-31 WO PCT/FR2001/001694 patent/WO2001092220A1/fr not_active Ceased
- 2001-05-31 ES ES01940654T patent/ES2219530T3/es not_active Expired - Lifetime
- 2001-05-31 AT AT01940654T patent/ATE264839T1/de not_active IP Right Cessation
- 2001-05-31 DE DE60102925T patent/DE60102925T2/de not_active Expired - Lifetime
-
2006
- 2006-03-28 US US11/390,480 patent/US8026231B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3920835A (en) | Treatment of disturbed keratinization | |
| RU2121995C1 (ru) | Полиеновые соединения, фармацевтическая и косметическая композиция на их основе | |
| JP2683390B2 (ja) | 局所適用のための医薬又は化粧品組成物 | |
| DE69205725T2 (de) | Iminoderivate, Verfahren zu ihrer Herstellung und ihre Verwendung in der Human- und Tiermedizin und in der Kosmetik. | |
| JPH029841A (ja) | 芳香族エステル及びチオエステル | |
| DE199636T1 (de) | Benzoenaphthalinderivate, verfahren zu deren herstellung und ihre verwendung in pharmazie und kosmetik. | |
| NL8403607A (nl) | 2.6-gedisubstitueerde naftaleenderivaten, werkwijze ter bereiding ervan en farmaceutische en cosmetische preparaten, die deze derivaten bevatten. | |
| KR100366200B1 (ko) | L-카르니틴염과이를함유한피부질환치료용화장품조성물및약제조성물 | |
| JP2003535076A5 (enExample) | ||
| JP2014159488A (ja) | ヘパラン硫酸の精製方法並びに美容用及び皮膚用調製物中におけるその使用 | |
| JPH10509987A (ja) | 二環式芳香族化合物 | |
| DE3707245C2 (de) | 2,3,4,4a-Tetrahydro-4a,10,10-trimethyl - 1H-3, 9b - methandibenzofuranderivate, Verfahren zur Herstellung dieser Verbindungen und pharmazeutische und kosmetische Mittel, die diese Verbindungen enthalten | |
| JP2015528499A (ja) | イデベノンとｎ−アセチル−ｓ−ファルネシル−ｌ−システインとエルゴチオネインとを含む調合物及びその使用法 | |
| WO2011025107A1 (ko) | 피부 가려움증 개선을 위한 조성물 | |
| EP0585130A2 (en) | External preparation for skin containing a depigmentation agent | |
| JP2000516219A (ja) | ケラチノサイト増殖を抑制する方法と組成物 | |
| US4877789A (en) | Eicosatriynoic acid esters and amides and their application in pharmaceutical and cosmetic practice | |
| JPH11507960A (ja) | 二環式芳香族化合物、これらを含有する組成物及びその使用 | |
| HU207980B (en) | Process for producing retinoides and pharmaceutical compositions containing them as active component | |
| BG63501B1 (bg) | Биароматни съединения и фармацевтични и козметични състави, които ги съдържат | |
| JP4855626B2 (ja) | 製薬分野における新規なアミノチオールエステル誘導体 | |
| CA2157837A1 (en) | L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses | |
| HRP20110134T1 (hr) | Novi agonistički ligandi rar receptora i njihova upotreba u ljudskoj medicini i kozmetici | |
| JP6778361B2 (ja) | フィラグリン遺伝子発現促進剤 | |
| CN105142727B (zh) | 甘草次酸亚酰胺基羟脯氨酸烷基酯和其受保护的衍生物 |